In adults with psoriasis, ustekinumab showed the highest drug survival rate in biologic-naive patients but had reduced effectiveness in biologic-experienced patients.
MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, ...
Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times that of Skyrizi in Phase 1, targeting the ...
Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...
My blood work showed that I was slightly low in vitamin D, so my doctor recommended that I take a supplement. My pharmacist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results